A monoclonal p53 antibody, the epitope recognised is in the N terminus of p53.
| Inventor | Institute |
|---|---|
| David Lane | University of Dundee |
| Cat. #: | 151292 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Apoptosis and autophagy;Cancer;Cell biology;Genetics |
| Application: | IHC ; IP ; WB |
| Target: | p53 (N terminus) |
| Reactivity: | Human |
| Clone: | Pab DO-2 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Vojtesek et al. 1992. J Immunol Methods. 151(1-2):237-44. PMID: 1378473. |
| Product description: | A monoclonal p53 antibody, the epitope recognised is in the N terminus of p53. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 53 kDa |
| Immunogen: | p53 |
| Target background: | p53 is a crucial tumour suppressor involved in over 50% of cancers. It acts as a stress-responsive transcription factor and plays a vital role in regulating cell cycle arrest, promoting apoptosis, maintaining genomic stability, controlling the cell cycle, and inhibiting angiogenesis. Known as the "guardian of the genome," p53 prevents gene mutations. Mutations in the p53 gene are common in human cancers, resulting in dysfunctional proteins unable to bind to DNA. This loss of function compromises p53's tumour suppressor activity. While p53 is typically found in low levels in healthy cells due to its short lifespan, disease states lead to increased expression driven by somatic mutations. This heightened expression is believed to contribute to cellular transformation and malignancy. DO-2 recognises an epitope specific for the N terminus region of p53, between aa 10-16. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | '-15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Sonnemann et al. 2011. Eur J Cancer. 47(9):1432-41. PMID: 21334198. Zaman et al. 2007. Cancer Res. 67(20):10078-86. PMID: 17942942. Stephen et al. 1995. J Mol Biol. 248(1):58-78. PMID: 7537340. Vojtesek et al. 1992. J Immunol Methods. 151(1-2):237-44. PMID: 1378473. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.